Ajanta Pharma
Ajanta Pharma Limited, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of a diverse range of formulations. Founded in 1973, the company has established a strong presence in various operational regions, including Asia, Africa, and the Middle East. Ajanta Pharma is renowned for its focus on therapeutic areas such as ophthalmology, dermatology, and pain management, offering unique products that cater to specific medical needs. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. Recognised for its robust market position, Ajanta Pharma continues to expand its global footprint, driven by a dedication to enhancing patient care through effective and affordable healthcare solutions.
DitchCarbon Score
How does Ajanta Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ajanta Pharma's score of 18 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ajanta Pharma's reported carbon emissions
In 2024, Ajanta Pharma, headquartered in India, reported significant carbon emissions totalling approximately 6,390,220 kg CO2e for Scope 1 and about 40,007,740 kg CO2e for Scope 2. This reflects a commitment to transparency in their environmental impact, although no data for Scope 3 emissions was disclosed. Comparatively, in 2023, the company recorded Scope 1 emissions of about 4,368,550 kg CO2e and Scope 2 emissions of approximately 51,813,330 kg CO2e. This indicates a slight increase in Scope 1 emissions year-on-year, while Scope 2 emissions decreased, suggesting a focus on improving energy efficiency. Ajanta Pharma has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. The absence of documented reduction targets suggests that while the company is actively reporting its emissions, it may benefit from establishing clear goals to enhance its sustainability efforts. Overall, Ajanta Pharma's emissions data highlights its operational footprint and underscores the importance of developing comprehensive climate strategies to mitigate its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 3,660,360 | 0,000,000 | 0,000,000 |
| Scope 2 | 41,756,300 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ajanta Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
